NFKB1 and acute kidney injury: Atorvastatin mitigates CI-AKI by suppressing the TLR4–MyD88–NF-κB signaling pathway, enhancing renal tubular epithelial cell activity, reducing cellular damage, and inhibiting both pyroptosis and inflammatory responses (Yue et al., 2023).